Kornimate/medical-research-clean huggingface dataset:
can imagination change upsetting memories of trauma?

Conditions: Psychosis

Summary: research suggests that imagination is a powerful tool to change images inside our heads (e.g. memories) and make them less upsetting. it is thought that this occurs through changing the meaning attached to the memory (e.g. i am weak), therefore making it less upsetting to remember. research has also linked some people's experience of psychosis to distressing trauma memories. despite this, little is known about whether using imagination to change memories is helpful for people with psychosis. this project will look at whether a talking therapy that uses imagination to change trauma memories helps people with psychosis. this project will specifically look at whether this therapy helps; change the meaning linked to memory, make the memory less upsetting and frequent, and increase sense of control over the memory. this project will recruit six to twelve people with psychosis. participants will be recruited from services within south london and the maudsley nhs foundation trust's psychosis clinical academic group. participants will first be interviewed about their posttraumatic stress difficulties, experiences of psychosis, mental health, and wellbeing. in this appointment, participants will also identify a traumatic memory to focus on during the talking therapy. four questions about the trauma memory will be asked every day for the remainder of the project. participants will then wait between one to three weeks before they receive three therapy sessions. comparing participants to themselves for different periods of time makes sure that their memories do not become less upsetting over time, without therapy. after therapy, participants will continue daily measures for two weeks, with an appointment in the middle (i.e. one week post therapy). this appointment will include questions about posttraumatic stress difficulties, wellbeing and satisfaction with therapy. participation will last between 6-8 weeks. participants will be reimbursed for their time


Eligibility criteria:
inclusion criteria: * diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features * able to identify an intrusive traumatic memory occurring at least twice in the past week, as assessed by the post traumatic stress diagnostic scale. * sufficient english to participate in the project exclusion criteria: * concurrent trauma-focused psychological therapy * primary diagnosis of learning disability, substance use or organic disorder * acute suicide risk * lack of capacity to provide informed consent

Keywords: imagery rescripting case series imrs psychosis
effectiveness study of nivolumab compared to chemotherapy in patients with relapsed small-cell lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed sclc.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed small cell lung cancer (sclc) * subjects with either limited or extensive disease stage at the initial diagnosis * must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage sclc * eastern cooperative oncology group (ecog) performance status 0 or 1 exclusion criteria: * untreated or symptomatic central nervous system (cns) metastases * prior therapy with anti-pd-1, anti-pdl1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody * inadequate hematologic or hepatic function
results of "four not techniques" in delayed and nonunion fractures of lateral humeral condyle in children

Conditions: Orthopaedic Surgery

Summary: fracture of lateral humeral condyle in children is not uncommon.the nonunion means no healing of the fracture after 3 months from the injury.delayed union means no healing from 6 weels to less than 3 months after injury. the treatment is difficult even surgery because of lack of blood supply of lateral condyle,unstability from muscle force and the articular fluid inhibition of union. the author try to improve the healing of the fracture after surgery by "4 not techniques", 1. the surgical approach should not enter posteriorly because the blood supply of lateral condyle enter posteriorly in order to avoid cut the vessels. 2. the dissection should not too much especially the muscle around the condyle. 3. it is not necessary to perfectly reduced the fracture after nonunion to avoid too much dissection the muscle and allow only healing of the fragment. 4. bone graft is not necessary. the author wants to know the results after perform "4 not technique" in delayed union and nonunion of lateral humeral condyle fracture

all children with delayed union or nonunion fracture lateral humeral condyle fractures will be inclued in the study. the children who received the previous surgery of the same elbow will be excluded. after full explanation and discussion to the children and parents.the surgery in "4 not technique" will be performed. 1. the lateral approach of the affected elbow and enter the fracture anteriorly. the approach should not enter posteriorly because the blood supply of lateral condyle enter posteriorly in order to avoid cut the vessels. 2. the dissection should not too much especially the muscle around the condyle. the nonunon fragment will be cleaned,washed and made until the healthy bone surface of fracture appear in both side of fracture. 3. it is not necessary to perfectly reduced the fracture after nonunion to avoid too much dissection the muscle and allow only healing of the fragment.the fixation by k-wires or screw in older children until the fragment is stable enough. 4. bone graft is not necessary but in valgus deformity the correctuve osteotomy should be performed to correct the valgus. the skin is closed,the long arm cast is put and change in 2 weeks interval until bone union. the measurement will be 1. the union rate 2. the carrying angle , baumann angle,shaft condylar angle 3. rom 4. complication of surgery such as infection,avn of troclear etc.

Eligibility criteria:
inclusion criteria: * all children less than 18 years old with delayed union and nonunion of fracture lateral humeral condyle exclusion criteria: * any previous surgery at the same elbow * refuse to participate the research
safety, tolerability, and clinical activity of asm-024 administered to patients with gold 2 or gold 3 chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: the purpose of this study is to evaluate the safety, tolerability, and clinical activity of asm-024 administered as a dry powder for inhalation formulation to patients with gold 2 or gold 3 copd.

this is a phase ii, randomized, double-blind, placebo-controlled, two-way crossover study to evaluate the safety, tolerability, and clinical activity of a new, dry powder for inhalation formulation of asm-024 administered twice daily for 14 days to patients with gold-2 or gold-3 copd.

Eligibility criteria:
inclusion criteria: * male or female adult aged over 40 yrs with a clinically confirmed diagnosis of copd at the severity stages of gold 2 (moderate) or 3 (severe); * stable copd for 1 month prior to screening * stable smoker for at least three months prior to screening, or non-smoker, with a smoking history of ≥ 10 packs years; * fev₁ ≥ 30 % and \< 70 % of the predicted normal value; * normal 12-lead ecg exclusion criteria: * clinically significant illness except copd or surgery within 8 weeks prior to first administration of the study medication; * significant medical history that, in the investigator's opinion, may adversely affect participation; * history of allergy or significant adverse reaction to drugs similar to asm-024, to nicotine, or to cholinergic drugs or any drugs with a similar chemical structure; * history of hypersensitivity (anaphylaxis, angioedema) to any drug; * positive pregnancy test for female subjects; * use of medications known to prolong qt/qtc interval; * clinically significant 12 lead ecg at screening; * clinically significant physical examination or laboratory findings or abnormal vital signs; * history of alcohol or drug abuse; * positive hepatitis b or c or hiv test at screening; * investigational drug within 30 days of screening; long-acting investigational drug within 90 days of screening; * previous exposure to asm-024; and * women of child-bearing potential and male participants unwilling or unable to use accepted methods of birth control.
cbd cigarettes instead of normal cigarettes as innovative treatment for schizophrenia

Conditions: Schizophrenia and Other Psychotic Disorders; Harm Reduction

Summary: interventional study using cannabidiol containing cigarettes as replacement of usual cigarettes reduction of enforcement measures, improved acute treatment, harm reduction, and improvement of psychotic symptoms


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or related disorders * panns \> 21, * tobacco-smokers * inpatient status * within age 18 - 65 years * german-speaking exclusion criteria: * personality disorder * non-smokers * organic psychotic diseases * breast feeding * pregnancy
brain effects of opiate agonist and antagonist

Conditions: Chronic Low-back Pain

Summary: this study will look at the short-term effect of morphine on brain response to food.

chronic low back pain patients and healthy controls will be recruited for this study. participants' brain will be scanned at baseline and then again on a different day after the administration of an oral dose of 30 mg morphine in an open label design. participants will receive morphine 60 minutes prior to the start of the second scanning session. the brain scans will include structural scans, functional scans at rest and functional scans during the ingestion of a highly caloric drink.

Eligibility criteria:
inclusion criteria: * healthy participants * patients in pain: suffering from persistent pain more days than not, 3/10 in intensity on a numerical rating scale, for at least 6 weeks or more. exclusion criteria: * any dsm diagnosis * diabetes * food allergies * lactose intolerance * participants seeking to quit smoking or to lose weight * participants on any psychotropic medication including opiate based analgesics (e.g. oxycodone, methadone, suboxone) * pregnant or nursing women * pacemaker or other implanted electrical devices * participants with a past history of head trauma or seizures * any past history of illegal drug or alcohol misuse * participants who cannot undergo an mri scan.
observational study to evaluate the safety and efficacy of levemir® in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in africa. the aim of this study is to assess the safety and efficacy of levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in algeria.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities * type 2 diabetes * hba1c between 7-9% * insulin naive * inadequate control with oral antidiabetics therapy as judged by investigator exclusion criteria: * patients with type 1 diabetes * hypersensitivity to levemir® or to any of the excipients * pregnancy, or desire of pregnancy within next 6 months * hba1c greater than or equal to 9% * known or suspected allergy to the trial product or to any of the excipients * subjects who are unlikely to comply with protocol
easego study: doubling of atorvastatin/simvastatin or inegy in patients with hypercholesterolemia and coronary artery disease(cad)(0653a-089)

Conditions: Atherosclerosis

Summary: in patients with coronary artery disease and a ldl-c level between 2.5 mmol/l and 5.0 mmol/l on a stable (\> 4 weeks) statin starting dose (simvastatin 20 mg or atorvastatin 10 mg), investigate what the lcl-c lowering efficacy is of doubling the statin dose (to 40 mg simvastatin or 20 mg atorvastatin) versus a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. it is postulated that more patients reach their ldl-c treatment goal with the combination tablet compared to doubling the starting dose. furthermore, the effect of both treatment regimens on other lipid parameters, safety and ldl-subfractions will be measured.

patients with simvastatin 20 mg or atorvastatin 10 mg were randomized to (1) double statin dose (to 40 mg simvastatin or 20 mg atorvastatin) or (2) switch to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks.

Eligibility criteria:
inclusion criteria: * patient is male or female 18 years of age. * patient is on a stable daily statin starting dose for the past 4 weeks of either: atorvastatin 10 mg or; simvastatin 20 mg * lipid values while on statin monotherapy treatment: ldl-c level of \> 2.5 mmol/l to \* 5.0 mmol/l, triglycerides \< 4.0 mmol/l and total cholesterol \< 7.0 mmol/l. * patient with established coronary artery disease such as stable angina; history of myocardial infarction; history of percutaneous coronary intervention (ptca with or without stent placement); coronary stenosis on angiography; history of unstable angina or non-q wave myocardial infarction; history of coronary artery bypass graft surgery (cabg); positive mibi scan. patients have to be in a stable medical condition. exclusion criteria: * patients in whom cholesterol lowering medication regime has changed in the previous 4 weeks. * patients who have been treated with any other investigational drug within 3 months of visit 1. * patients who are pregnant or lactating. * any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or interfere with participation in the study.
colonoscopy outreach for rural communities aim 2

Conditions: Colorectal Cancer

Summary: this study aims to test the effectiveness of a patient navigation program for increasing colonoscopy completion for colorectal cancer screening, among rural populations. the study will partner with geographically disparate primary care organizations to recruit patients aged 45-75 to the study. the patient navigation program will be delivered through a community organization. this project is critical in advancing our knowledge of the effectiveness of patient navigation for increasing colonoscopy in this patient population as well as for understanding factors that can support long term implementation and sustainability of effective interventions.

colorectal cancer (crc) is a leading cause of cancer death in the united states and its burden is greater in rural and low-income communities. failure to complete recommended colonoscopy contributes to later-stage crc diagnosis and worse crc outcomes, which means timely and successful colonoscopy is a key opportunity to reduce crc mortality. using a type 1 hybrid implementation-effectiveness design, we will randomize 480-600 subjects from 6-8 primary care clinical organizations in a randomized controlled trial (rct) to accomplish the following: * test the effectiveness of a patient navigation program delivered by a community-based organization, for increasing colonoscopy completion rates for colorectal cancer screening among rural patients. * assess implementation and sustainability of the patient navigation program from the perspectives of both community and clinical stakeholders.

Eligibility criteria:
inclusion criteria: * aged 45-76.25 on the date of their referral for colonoscopy * referred for colonoscopy as part of colorectal cancer screening in the last 3 months. this includes patients referred for colonoscopy after an abnormal stool screening test (e.g., fit/fobt/cologuard) and patients referred for colonoscopy as a primary screening test for colorectal cancer. exclusion criteria: * deceased * colonoscopy procedure since colonoscopy referral * colonoscopy procedure scheduled less than or equal to 7 days from study enrollment date * colonoscopy procedure scheduled more than 9 months from colonoscopy referral date (if known at enrollment) * have diagnosis or past history of total colectomy or colorectal cancer (malignant neoplasm) at any time * has hospice * aged 66 and older living long-term in an institution for more than 90 consecutive days during the year prior to the query

Keywords: colorectal cancer patient navigation colonoscopy fit fecal immunochemical test immunochemical fecal occult blood test implementation effectiveness colorectal cancer screening
efficacy, safety and tolerability of icatibant for the treatment of hae

Conditions: Hereditary Angioedema

Summary: the investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered icatibant for the treatment of acute attacks of hereditary angioedema. the investigators believe that self administration with icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with icatibant in a medical facility.


Eligibility criteria:
inclusion criteria: 1. males and females at least 18 years of age at the time of informed consent 2. documented diagnosis of hereditary angioedema type i or ii based on all of the following criteria: * family and/or medical history * characteristic attack manifestations, recurrent attacks * historical low c4, normal c1q and either low c1-inh or low c1inh function 3. women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year), sexual abstinence or have a vasectomised partner during the duration of the study. hormonal contraception can be continued if verified by a physician that it doesn't affect the course of hereditary angioedema attacks. 4. mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures. 5. ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient. exclusion criteria: 1. participation in a clinical therapeutic trial of another investigational medicinal product within the past month (except a previous icatibant study). 2. diagnosis of angioedema other than type i or type ii hereditary angioedema. 3. evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease. 4. congestive heart failure (nyha class 3 and 4). 5. stroke within the past 6 months. 6. treatment with angiotensin converting enzyme inhibitor. 7. pregnancy and/or breast-feeding. 8. in the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study. 9. in the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason. 10. in the opinion of the investigator: inability to complete the patient diary, manage study medication or self-administration of an injection.
study of micrornas as a diagnostic tool for hcv-related hepatocellular carcinoma

Conditions: miRna in HCC

Summary: the aim of this work is to study the role of circulating mirnas in diagnosis of hcv related hepatocellular carcinoma.

early diagnosis of hepatocellular carcinoma can significantly improve the overall survival of hcc patients, currently available diagnostic markers are still inadequate and limited by their low sensitivity and specificity. for instance, the gold standard marker, alpha-fetoprotein (afp), has a false negative rate up to 40% for early stage of hcc. it is worthy to mention that the level of afp was reported in a normal range of 25% of patients with advanced hcc. these discrepancies suggest the need of discovering new reliable diagnostic markers for patients with hcc. mirnas are small endogenous, non-coding, ssrna that are 21-30 nucleotides in length. as for the relationship between mirna and hcc several studies have demonstrated that the aberrant expression of specific mirna can be detected in hcc cells and tissues. mirnas expression profile analysis has allowed the characterization of 'identity' associated with each type of human cancer and this 'identity' is correlated with carcinogenesis, tumor progression, and response to tumor treatment.

Eligibility criteria:
inclusion criteria: * rna extraction and quantitative real-time pcr analysis * diagnosis of hcv will be based on detection of anti-hcv antibodies * diagnosis of liver cirrhosis will be based on ultrasonography, biochemically and elastography when available * diagnosis of hcc will be based on ultrasonography, the typical criteria in triphasic multislice ct scan exclusion criteria: * hbv or autoimmune or metabolic liver disease * serological evidence of human immunodeficiency virus (hiv) infection * malignancy in other organs * after intervention in treatment of hepatocellular carcinoma
cross-sectional dietary intake survey on ivorian school-aged children and women of reproductive age

Conditions: Diet; Deficiency

Summary: a cross-sectional dietary intake study was conducted with 423 ivorian school aged children (sac, 6-12 years) and 423 women of reproductive age (wra, 15-49 years) from four cities, recruited by two-stage random sampling.

a cross-sectional dietary intake study was conducted with 423 ivorian school aged children (sac, 6-12 years) and 423 women of reproductive age (wra, 15-49 years) from four cities, recruited by two-stage random sampling. dietary intake data were collected by multiple pass 24-hour recall. for a sub-sample (10% subjects) two-day non-consecutive multiple pass 24-hour recall was collected.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * illness or disease

Keywords: nutrient inadequacy dietary patterns food intake
regulation of inflammatory parameters by telmisartan in hypertensive patients

Conditions: Hypertension; Metabolic Syndrome; Hypertriglyceridemia

Summary: a number of studies have shown that certain blood-pressure medications such as ace-inhibitors and angiotensin-ii-receptor blockers (arb) can reduce the incidence of diabetes mellitus type 2. this protocol will evaluate whether inflammatory mechanisms mediate this effect. the investigators therefore will investigate the effect of telmisartan, a potent arb, on lipid metabolism, glucose metabolism and inflammation in patients with the metabolic syndrome. specific parameters will be tested before treatment and after 3 months of treatment. placebo will be compared to 2 different doses of telmisartan per day.


Eligibility criteria:
inclusion criteria: * abd. obesity (bmi\>25kg/m²) and waist circumference ≥95cm (men),≥80cm (women) * blood pressure ≥130 mmhg (systolic) and/or ≥85 mmhg (diastolic) * triglycerides 150-400 mg/dl * normal stress test * normal carotid ultrasound * normal fundoscopy exclusion criteria: * diabetes mellitus * secondary cause for insulin resistance * ldl-cholesterol \>190 mg/dl * atherosclerotic disease * blood pressure \>160 mmhg (systolic) and/or \>100 mmhg (diastolic) * regular alcohol consumption (\>30 g/day) * contraindication against telmisartan * antihypertensive medications * lipid lowering therapy * malignancy * pregnancy or lactation * women without adequate contraception
therapeutic management and use of resources and costs of spinal muscular atrophy in spain

Conditions: Spinal Muscular Atrophy Type I; Spinal Muscular Atrophy Type II

Summary: an observational, retrospective, cross-sectional, multicenter study. real-world data were obtained from medical records of spanish public hospitals (9 hospitals).


Eligibility criteria:
inclusion criteria: * patients diagnosed with sma type i or sma type ii. * patients with medical records available in the hospital. * patients diagnosed with sma type i or sma type ii after 2017 for whom a minimum of 6 months of follow-up was available. exclusion criteria: • patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.